dorsaVi USA Market Update 
CLICK HERE TO CONTACT dorsaVi

Key points:

  • New contracts signed in the US in the last month exceeding AUD$250,000
  • Large OHS contracts generated from new relationship with WorkRight NW
  • Physiotherapy Associates clinical network roll out ahead of schedule with 15 clinics now using dorsaVi’s technology; strong support for continued rapid expansion 
  • Heightened awareness following NBA basketball playoffs resulting in new ViPerform signings

​​

Melbourne, Australia – 6 July 2016: Medical device company dorsaVi Ltd (ASX: DVL) is pleased to report major commercial activity in the USA and a strong pipeline of large contracts currently under negotiation.  In the last month, dorsaVi has signed new contracts with a commercial value totalling more than AUD$250,000.  

The company is pleased to provide an update on its US operations.

Occupational Health & Safety 
dorsaVi USA is approaching the Occupational Health & Safety (OHS) opportunities through two channels; direct via dorsaVi sales representatives, and in partnership with a number of organisations who provide complementary workplace health and safety consulting and/or solutions in key markets across the country.
 
In partnership with WorkRight NW, an innovative injury prevention company, dorsaVi has secured two large contracts in the past month which are collectively valued at more than AUD$230,000.
 
President of WorkRight NW, Nic Patee said: “We believe that the dorsaVi ViSafe solution for workplace health will address a number of issues our customers are facing – increasingly they are looking for reliable data to support business decisions within their organisations. The dorsaVi solution is resonating well, and customers like the fact that the technology is medical-grade giving them confidence in the data. Further we have a growing number of reference customers which also provides a level of reassurance.”   
 
Last month dorsaVi USA signed a contract with the National Institute of Safety and Health (NIOSH) to provide them with two sets of the dorsaVi movement sensors. NIOSH initially plan to use the technology to conduct a number of lower back assessments.
 
NIOSH is part of the U.S. Centers for Disease Control and Prevention, in the U.S. Department of Health and Human Services. It has the mandate to assure “every man and woman in the Nation safe and healthful working conditions and to preserve our human resources.” NIOSH has more than 1,300 employees from a diverse set of fields including epidemiology, medicine, nursing, industrial hygiene, safety, psychology, chemistry, statistics, economics, and many branches of engineering.  
 
Clinical market
In late February, dorsaVi announced that Physiotherapy Associates (www.myphysio.com), a leading national provider of physical and occupational outpatient rehabilitation services in the US, had signed an initial pilot program to offer dorsaVi wearable wireless sensors to assess sports medicine patients. The terms of the agreement include implementation of 20 ViPerform units across 20 sites during the first 12-months. 
 
Physiotherapy Associates’ parent company Select Medical Corporation, one of the largest operators of specialty hospitals and outpatient rehabilitation clinics in the US, has now commenced a small pilot program utilising dorsaVi’s technology as part of its rehabilitation services. In the first three months, dorsaVi’s technology has been introduced into 15 sites, across the Select Medical and Physiotherapy Associates network, ahead of the planned rollout schedule of 10 clinics.
 
Sports Market
The recent focus on the NBA Playoffs has provided heightened awareness of ViPerform via The Golden State Warriors who have been using ViPerform since last year. A number of other NBA teams are now using the dorsaVi technology and additional sales are expected through organic referral.
 
Mark Heaysman, Head of Sales and Operations USA said: “The market in the US for our technology is massive and our approach to support multiple sales channels is proving successful and is allowing us to drive a more rapid ramp up of our operations in the US.  Our contract size has also increased substantially with multiple contract signings in excess of AUD$100,000. We also expect to see repeat business with a number of large organisations.”
 
“It is rewarding to see the investment we’ve made in the US market over the last 12 months now delivering returns. I’m excited about the coming year as we’re well placed to leverage the relationships we’ve put in place and make further inroads in the US market.”
 

ENDS –

Key points:

  • New contracts signed in the US in the last month exceeding AUD$250,000
  • Large OHS contracts generated from new relationship with WorkRight NW
  • Physiotherapy Associates clinical network roll out ahead of schedule with 15 clinics now using dorsaVi’s technology; strong support for continued rapid expansion 
  • Heightened awareness following NBA basketball playoffs resulting in new ViPerform signings

​​

Melbourne, Australia – 6 July 2016: Medical device company dorsaVi Ltd (ASX: DVL) is pleased to report major commercial activity in the USA and a strong pipeline of large contracts currently under negotiation.  In the last month, dorsaVi has signed new contracts with a commercial value totalling more than AUD$250,000.  

The company is pleased to provide an update on its US operations.

Occupational Health & Safety 
dorsaVi USA is approaching the Occupational Health & Safety (OHS) opportunities through two channels; direct via dorsaVi sales representatives, and in partnership with a number of organisations who provide complementary workplace health and safety consulting and/or solutions in key markets across the country.
 
In partnership with WorkRight NW, an innovative injury prevention company, dorsaVi has secured two large contracts in the past month which are collectively valued at more than AUD$230,000.
 
President of WorkRight NW, Nic Patee said: “We believe that the dorsaVi ViSafe solution for workplace health will address a number of issues our customers are facing – increasingly they are looking for reliable data to support business decisions within their organisations. The dorsaVi solution is resonating well, and customers like the fact that the technology is medical-grade giving them confidence in the data. Further we have a growing number of reference customers which also provides a level of reassurance.”   
Last month dorsaVi USA signed a contract with the National Institute of Safety and Health (NIOSH) to provide them with two sets of the dorsaVi movement sensors. NIOSH initially plan to use the technology to conduct a number of lower back assessments.
 
NIOSH is part of the U.S. Centers for Disease Control and Prevention, in the U.S. Department of Health and Human Services. It has the mandate to assure “every man and woman in the Nation safe and healthful working conditions and to preserve our human resources.” NIOSH has more than 1,300 employees from a diverse set of fields including epidemiology, medicine, nursing, industrial hygiene, safety, psychology, chemistry, statistics, economics, and many branches of engineering.  
 
Clinical market
In late February, dorsaVi announced that Physiotherapy Associates (www.myphysio.com), a leading national provider of physical and occupational outpatient rehabilitation services in the US, had signed an initial pilot program to offer dorsaVi wearable wireless sensors to assess sports medicine patients. The terms of the agreement include implementation of 20 ViPerform units across 20 sites during the first 12-months. 
 
Physiotherapy Associates’ parent company Select Medical Corporation, one of the largest operators of specialty hospitals and outpatient rehabilitation clinics in the US, has now commenced a small pilot program utilising dorsaVi’s technology as part of its rehabilitation services. In the first three months, dorsaVi’s technology has been introduced into 15 sites, across the Select Medical and Physiotherapy Associates network, ahead of the planned rollout schedule of 10 clinics.
 
Sports Market
The recent focus on the NBA Playoffs has provided heightened awareness of ViPerform via The Golden State Warriors who have been using ViPerform since last year. A number of other NBA teams are now using the dorsaVi technology and additional sales are expected through organic referral.
 
Mark Heaysman, Head of Sales and Operations USA said: “The market in the US for our technology is massive and our approach to support multiple sales channels is proving successful and is allowing us to drive a more rapid ramp up of our operations in the US.  Our contract size has also increased substantially with multiple contract signings in excess of AUD$100,000. We also expect to see repeat business with a number of large organisations.”
 
“It is rewarding to see the investment we’ve made in the US market over the last 12 months now delivering returns. I’m excited about the coming year as we’re well placed to leverage the relationships we’ve put in place and make further inroads in the US market.”
 

ENDS –

Request more information about our technology

CONTACT ME FOR MORE INFORMATION

Randomized Controlled Trial with dorsaVi technology finds back pain patients monitored and treated using dorsaVi's sensors had significant, sustained improvements in pain and function.

Recent news: What's happening at dorsaVi 

ViPerform and the NFL: How Loren Landow uses objective data to assess risk of injury

Fix the following errors:
Hide